US 12,187,766 B2
Compositions and methods for treating SARS-CoV-2 infections
Venkataramanan Soundararajan, Andover, MA (US); Murali Aravamudan, Andover, MA (US); Arjun Puranik, San Jose, CA (US); Praveen Anand, Bangalore (IN); and Aiveliagaram Venkatakrishnan, Cambridge, MA (US)
Assigned to nference, Inc., Cambridge, MA (US)
Filed by nference, Inc., Cambridge, MA (US)
Filed on May 2, 2022, as Appl. No. 17/734,653.
Claims priority of provisional application 63/183,140, filed on May 3, 2021.
Prior Publication US 2022/0372082 A1, Nov. 24, 2022
Int. Cl. C07K 16/40 (2006.01); A61P 31/12 (2006.01); C07K 14/005 (2006.01)
CPC C07K 14/005 (2013.01) [A61P 31/12 (2018.01); C07K 16/40 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A method of treating or reducing viral infection in a human subject, comprising administering to the human subject a pharmaceutical composition comprising a protease inhibitor and Proprotein Convertase Subtilisin/Kexin Type 2 (PCSK2), wherein the protease inhibitor prevents a protease from cleaving a peptide at a cleavage site, wherein the cleavage site results in mimicry of a peptide on the human epithelial sodium channel α-subunit (ENaC-α).